Results 131 to 140 of about 4,268 (199)

Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort

Background: Real-world data showing the long-term effectiveness of long-acting injectable cabotegravir and rilpivirine are scarce. We assessed the effectiveness of cabotegravir and rilpivirine in all individuals who switched to cabotegravir and ...
van der Valk, Marc, Global Health, Sigaloff, Kim C.E., Soetekouw, Robert, Wit, Ferdinand W.N.M., Infection & Immunity, van Eeden, Arne, Stalenhoef, Janneke, Boyd, Anders, Burger, David, Gisolf, Jet, Wensing, Annemarie M.J., El Moussaoui, Rachida, MS Reumatologie/Immunologie/Infectie, Brouwer, Annemarie E., Mudrikova, Tatiana, Jongen, Vita W., ATHENA National Observational HIV Cohort   +17 more
core  

Correction to “Mechanistic Basis of Cabotegravir–Glucuronide Disposition in Humans” [PDF]

The Journal of Pharmacology and Experimental Therapeutics, 2019
openaire   +2 more sources

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval. [PDF]

Antimicrob Agents Chemother
Charpentier C, Montrouge T, Wirden M, Avettand-Fenoel V, Tumiotto C, Bellecave P, Rodallec A, Garnier E, Fofana D, Lambert-Niclot S, Montès B, Chaix M-L, Charre C, Gantner P, Bouvier-Alias M, Alidjinou EK, Coulon P, Mchantaf G, Beby-Defaux A, Alessandri-Gradt E, Moisan A, Le Hingrat Q, Lê M, Delaugerre C, Marcelin A-G, Peytavin G, Calvez V, Descamps D, Lenacapavir Observatory Study Group.   +28 more
europepmc   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management "ADAPT" Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa. [PDF]

HIV AIDS (Auckl)
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F.   +4 more
europepmc   +1 more source

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study. [PDF]

Lancet HIV
Gaur AH, Baltrusaitis K, Capparelli EV, Moye JH, Yin DE, Masheto G, Buisson S, Harrington CM, Marzinke MA, Lowenthal ED, Scheckter R, Ace A, Ward S, Milligan R, Whitson K, Huang J, Cheung SYA, Best BM, Townley E, Roberts G, Kakuda TN, Birmingham E, Mathiba SR, Aurpibul L, Korutaro V, Smith C, Patel F, Moodley E, Bolton-Moore C, IMPAACT 2017 Collaborators, IMPAACT 2017 Team.   +30 more
europepmc   +1 more source

Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery. [PDF]

Open Forum Infect Dis
Davis JM, O'Neill J, Lyden E, Bares SH.
europepmc   +1 more source

Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study. [PDF]

Open Forum Infect Dis
Rosas Cancio-Suárez M, Moreno A, Terrón SDC, Vivancos MJ, Vélez Díaz-Pallarés M, Casado JL, Cano C, Navarro-Soler R, Moreno S, Pérez-Elías MJ.   +9 more
europepmc   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. [PDF]

CPT Pharmacometrics Syst Pharmacol
Renou Q, Néant N, Destere A, Lagoutte-Renosi J, Grégoire M, Parant F, Lalanne S, Lemaitre F, Gandia P, Venisse N, Bouchet S, Lê MP, Muret P, Peytavin G, Solas C, Benaboud S, CARLA Study Group.   +16 more
europepmc   +1 more source

Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible. [PDF]

Infez Med
Cossu MV, D'Avolio A, Ridolfo AL, Moschese D, Gori A, Cattaneo D, Gervasoni C.   +6 more
europepmc   +1 more source